Repositioning Candidate Details
| Candidate ID: | R0684 |
| Source ID: | DB05048 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | Cannabinor |
| Synonyms: | -- |
| Molecular Formula: | C28H38O6 |
| SMILES: | [H][C@]12C[C@]([H])(C(=O)C[C@@H]1C1=C(O)C=C(C=C1OC(=O)\C=C\C(O)=O)C(C)(C)CCCCCC)C2(C)C |
| Structure: |
|
| DrugBank Description: | Cannabinor, a synthetic CB2-selective agonist, is in Phase 2 clinical testing as an analgesic. |
| CAS Number: | 573981-31-4 |
| Molecular Weight: | 470.606 |
| DrugBank Indication: | Investigated for use/treatment in pain (acute or chronic). |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | CB2 agonists bind to CB2 receptors, which are located on immune and inflammatory cells. By activating CB2 receptors, CB2 agonists inhibit autoimmune and inflammatory processes and are likely to be useful for treating pain, autoimmune and inflammatory disorders. Pharmos is developing its CB2 agonists as treatments for chronic pain and autoimmune diseases such as multiple sclerosis and rheumatoid arthritis. |
| Targets: | -- |
| Inclusion Criteria: | Therapeutic strategy associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I15 | 1290 | Bone disease | A connective tissue disease that affects the structure or development of bone or causes an impairment of normal bone function. http://en.wikipedia.org/wiki/Bone_disease | disease of anatomical entity/ musculoskeletal system disease/connective tissue disease | Details |